Trio of new studies help clarify role of abciximab


Abciximab reduces nonfatal outcomes as part of a new reperfusion regimen for acute myocardial infarction (MI) but appears not to benefit patients with acute coronary syndromes who don't undergo early revascularization.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.